News
- Author:
- Susan London
Publish date: January 20, 2014
Major finding: Capecitabine and infused 5-FU yielded statistically indistinguishable rates of locoregional control approaching 90%.
News
- Author:
- Susan London
Publish date: January 17, 2014
Major finding: The overall response rate was 43% and the clinical benefit rate was 97%.
Data source: A randomized phase II trial among 28 patients...
News
- Author:
- Susan London
Publish date: January 16, 2014
Major Finding: Compared with GVAX alone, GVAX followed by CRS-207 was associated with better overall survival (6.1 vs. 3.9 months; hazard ratio, 0...
News
- Author:
- Susan London
Publish date: January 15, 2014
Major finding: Patients with the extended set of RAS mutations derived little to no benefit when panitumumab was added to FOLFIRI chemotherapy: 15...
News
- Author:
- Susan London
Publish date: January 14, 2014
Major finding: Compared with placebo plus paclitaxel, ramucirumab plus paclitaxel was associated with significantly better median overall survival...
News
- Author:
- Susan London
Publish date: December 27, 2013
Major finding: There was no significant difference in overall survival with surgery vs. systemic therapy in either the Indian trial (5-year rate, ...
News
- Author:
- Susan London
Publish date: December 20, 2013
News
- Author:
- Susan London
Publish date: December 20, 2013
News
- Author:
- Susan London
Publish date: December 17, 2013
Major finding: Carboplatin improved the odds of pCR by 71%-76% with some additional toxicity; bevacizumab improved the odds of pCR by 58% with con...
News
- Author:
- Susan London
Publish date: December 16, 2013
Major finding: Among patients with triple-negative disease, there was a 90% predictive probability that veliparib-carboplatin added to chemotherap...
News
- Author:
- Susan London
Publish date: December 13, 2013
News
- Author:
- Susan London
Publish date: December 13, 2013
Major Finding: The rate of invasive disease–free survival did not differ significantly between patients on bevacizumab and those who were no...
News
- Author:
- Susan London
Publish date: December 12, 2013
Major finding: Adding dasatinib to letrozole did not improve the clinical benefit rate, but it more than doubled median progression-free survival ...
News
- Author:
- Susan London
Publish date: December 12, 2013
Major Finding: Women who experienced a pCR were 62% less likely to have events such as recurrences and second primaries, and 65% less likely to di...
News
- Author:
- Susan London
Publish date: December 6, 2013
Major finding: At 6 months, there was a sustained, more than one-half reduction from baseline in esophageal acid exposure and a two-thirds reducti...
